Zimmer Biomet Holdings Total Cost of Revenue decreased by 27.3% to $576.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.8%, from $549.80M to $576.20M. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 6.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $496.20M | $491.40M | $536.50M | $500.00M | $511.00M | $488.20M | $520.30M | $500.80M | $525.50M | $518.60M | $538.80M | $512.30M | $553.60M | $538.60M | $586.70M | $549.80M | $592.20M | $559.30M | $792.40M | $576.20M |
| QoQ Change | — | -1.0% | +9.2% | -6.8% | +2.2% | -4.5% | +6.6% | -3.7% | +4.9% | -1.3% | +3.9% | -4.9% | +8.1% | -2.7% | +8.9% | -6.3% | +7.7% | -5.6% | +41.7% | -27.3% |
| YoY Change | — | — | — | — | +3.0% | -0.7% | -3.0% | +0.2% | +2.8% | +6.2% | +3.6% | +2.3% | +5.3% | +3.9% | +8.9% | +7.3% | +7.0% | +3.8% | +35.1% | +4.8% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Americas | $267.60M | $281.10M | $270.90M | $315.20M | $297.80M |
| EMEA | $165.80M | $169.80M | $160.30M | $187.50M | $186.40M |
| Asia Pacific | $83.30M | $118.60M | $116.40M | $119.00M | $88.00M |
| Total | $549.80M | $592.20M | $559.30M | $792.40M | $576.20M |